GRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Galera Therapeutics's cost of goods sold for the three months ended in Mar. 2024 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Galera Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was %.
Cost of Goods Sold is also directly linked to Inventory Turnover.
The historical data trend for Galera Therapeutics's Cost of Goods Sold can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galera Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cost of Goods Sold | Get a 7-Day Free Trial | - | - | - | - | - |
Galera Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cost of Goods Sold | Get a 7-Day Free Trial | - | - | - | - | - |
Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.
Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galera Therapeutics (NAS:GRTX) Cost of Goods Sold Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Galera Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:
Gross Margin % | = | (Revenue | - | Cost of Goods Sold) | / | Revenue |
= | (0 | - | 0) | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:
Galera Therapeutics's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Galera Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Bachleda | officer: Chief Commercial Officer | C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355 |
Chris Degnan | officer: Chief Financial Officer | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Mel Sorensen | director, officer: President and CEO | 7 RAPPS RUN DRIVE, MALVERN PA 19355 |
Eugene P. Kennedy | officer: Chief Medical Officer | 2503 SOUTH LOOP DRIVE, AMES IA 50010 |
Linda West | director | C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355 |
Jennifer Evans Stacey | officer: See Remarks | AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401 |
Jon T Holmlund | officer: Chief Medical Officer | |
Lawrence M Alleva | director | 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Novo Holdings A/s | 10 percent owner, other: SEE REMARKS | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Joel F. Sussman | officer: Chief Accounting Officer | C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355 |
Novartis Bioventures Ltd | 10 percent owner | C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000 |
New Enterprise Associates 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Clarus Iv-a, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Blackstone Clarus Gp L.p. | 10 percent owner | C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154 |
Sofinnova Venture Partners Ix, L.p. | 10 percent owner | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
From GuruFocus
By sperokesalga sperokesalga • 05-01-2023
By Ds*** Ds*** • 09-01-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 05-11-2023
By GuruFocusNews GuruFocusNews • 06-29-2022
By Value_Insider Value_Insider • 10-26-2022
By Value_Insider Value_Insider • 11-22-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.